A detailed history of Kestra Advisory Services, LLC transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Kestra Advisory Services, LLC holds 92,519 shares of CTXR stock, worth $289,584. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92,519
Previous 93,589 1.14%
Holding current value
$289,584
Previous $54,000 14.81%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$0.48 - $1.02 $513 - $1,091
-1,070 Reduced 1.14%
92,519 $46,000
Q2 2024

Aug 14, 2024

BUY
$0.58 - $1.03 $7,365 - $13,081
12,700 Added 15.7%
93,589 $54,000
Q1 2024

May 15, 2024

BUY
$0.6 - $0.9 $5,079 - $7,619
8,466 Added 11.69%
80,889 $72,000
Q4 2023

Feb 14, 2024

SELL
$0.65 - $0.86 $12,492 - $16,528
-19,219 Reduced 20.97%
72,423 $55,000
Q3 2023

Nov 09, 2023

BUY
$0.65 - $1.25 $650 - $1,250
1,000 Added 1.1%
91,642 $62,000
Q2 2023

Aug 11, 2023

SELL
$1.08 - $1.65 $1,377 - $2,103
-1,275 Reduced 1.39%
90,642 $108,000
Q1 2023

May 12, 2023

SELL
$0.78 - $1.42 $1,404 - $2,556
-1,800 Reduced 1.92%
91,917 $107,000
Q4 2022

Jan 31, 2023

BUY
$0.79 - $1.28 $4,380 - $7,097
5,545 Added 6.29%
93,717 $74,000
Q3 2022

Nov 01, 2022

BUY
$0.14 - $1.33 $2,389 - $22,703
17,070 Added 24.01%
88,172 $107 Million
Q2 2022

Aug 12, 2022

BUY
$0.88 - $1.87 $27,249 - $57,904
30,965 Added 77.15%
71,102 $65,000
Q1 2022

Apr 26, 2022

SELL
$1.38 - $1.89 $4,278 - $5,859
-3,100 Reduced 7.17%
40,137 $71,000
Q4 2021

Jan 20, 2022

BUY
$1.51 - $2.2 $3,441 - $5,013
2,279 Added 5.56%
43,237 $66,000
Q3 2021

Oct 19, 2021

BUY
$1.74 - $2.6 $71,266 - $106,490
40,958 New
40,958 $83,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $457M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track This Portfolio

Track Kestra Advisory Services, LLC Portfolio

Follow Kestra Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kestra Advisory Services, LLC with notifications on news.